EGFR and neoplasm: Furthermore, they can be surface-modified with targeting molecules, such as antibodies, peptides, or folate, to bind tumor-associated receptors like HER 2, EGFR, the transferrin receptor, and αvβ3 integrins, enhancing targeted delivery and minimizing off-target toxicity [219].